JHOP - August 2020 Vol 10, No 4
Pharmacist-Run Chemotherapy-Induced Nausea and Vomiting Management Protocol Improves Patient Outcomes and Benefits Physician Workflow
Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy
Oral oncolytic therapy is increasingly prescribed for patients with hematologic malignancies, but several barriers prevent or delay medication initiation, including insurance approval, financial assistance, limited distribution drug networks, and off-label use. Many oral therapies require insurance approval before they can be dispensed, and patients frequently need financial assistance for copays once a medication is approved.
The rising costs of cancer care and the aging US population pressure healthcare systems to deliver high-value care while managing costs. Chemotherapy drug prices continue to increase with advances in precision medicine and immunotherapy, with Medicare bearing the larger burden of costs.
Progression of Metastatic, PD-L1–Positive, Ampullary Carcinoma with a Treatment Holiday from Off-Label Use of Pembrolizumab Therapy
Fulvestrant and palbociclib are each approved for the treatment of HR-positive metastatic breast cancer, and can also be used in combination. Cases of hepatotoxicity and elevated liver enzymes have been documented with each agent when used as monotherapy.
The following select abstracts were presented during the poster presentation at the 16th Annual Conference of the Hematology/Oncology Pharmacy Association (HOPA) in Tampa, FL, in April 2020. Some abstracts were published in the June issue of the journal and the balance of the 2020 abstracts will be published in October and December.
Results 1 - 6 of 6